SG10202011033QA - Phthalocyanine dye conjugates and their storage - Google Patents

Phthalocyanine dye conjugates and their storage

Info

Publication number
SG10202011033QA
SG10202011033QA SG10202011033QA SG10202011033QA SG10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA SG 10202011033Q A SG10202011033Q A SG 10202011033QA
Authority
SG
Singapore
Prior art keywords
storage
phthalocyanine dye
dye conjugates
conjugates
phthalocyanine
Prior art date
Application number
SG10202011033QA
Inventor
Lewis Makings
Roger Heim
Miguel Garcia-Guzman
Eileen Chin
Deepak Yadav
Jerry Fong
Original Assignee
Rakuten Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakuten Medical Inc filed Critical Rakuten Medical Inc
Publication of SG10202011033QA publication Critical patent/SG10202011033QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
SG10202011033QA 2015-08-18 2016-08-18 Phthalocyanine dye conjugates and their storage SG10202011033QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562206774P 2015-08-18 2015-08-18

Publications (1)

Publication Number Publication Date
SG10202011033QA true SG10202011033QA (en) 2020-12-30

Family

ID=56801860

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202011033QA SG10202011033QA (en) 2015-08-18 2016-08-18 Phthalocyanine dye conjugates and their storage

Country Status (11)

Country Link
US (2) US11141483B2 (en)
EP (2) EP3337568B1 (en)
JP (4) JP7055742B6 (en)
CN (4) CN114699525A (en)
AU (1) AU2016308286B2 (en)
CA (1) CA2994871A1 (en)
DK (1) DK3337568T3 (en)
ES (1) ES2889904T3 (en)
NZ (1) NZ739788A (en)
SG (1) SG10202011033QA (en)
WO (1) WO2017031363A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
SG11201610052TA (en) 2014-08-08 2017-02-27 Us Health Photo-controlled removal of targets in vitro and in vivo
CN108137701A (en) 2015-08-07 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) For treating cancer for the near infrared light immunotherapy (NIR-PIT) for inhibiting cell
CN114699525A (en) * 2015-08-18 2022-07-05 乐天医药生技股份有限公司 Method for producing phthalocyanine dye conjugate and stable conjugate
EP3827846A1 (en) 2015-08-18 2021-06-02 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10682602B2 (en) * 2017-01-19 2020-06-16 National University Of Singapore Nanofibrous filter
EP3585433A4 (en) * 2017-02-23 2020-12-30 Rakuten Medical, Inc. Therapeutic compositions and related methods for photoimmunotherapy
CN111526730B (en) 2017-12-29 2024-02-23 卡夫食品集团品牌有限责任公司 Improved oxidative stability of oil-in-water emulsions using natural stabilizers
WO2019172110A1 (en) * 2018-03-09 2019-09-12 学校法人慈恵大学 Conjugate of antibody targeting blood vessels and photosensitizer
AU2019276572A1 (en) 2018-06-01 2020-12-24 Rakuten Medical, Inc. Phthalocyanine dye conjugate compositions
US20220226402A1 (en) * 2019-03-25 2022-07-21 Northshore University Health System Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
EP3946631A1 (en) * 2019-03-26 2022-02-09 Shimadzu Corporation Photoimmunotherapy and pharmaceutical agent used therefor
CN115943306A (en) 2019-03-29 2023-04-07 乐天医药生技股份有限公司 Methods and related biomarkers for photoimmunotherapy
JPWO2020246350A1 (en) * 2019-06-03 2020-12-10
CN114585391A (en) * 2019-08-07 2022-06-03 乐天医药生技股份有限公司 Cetuximab-IR 700 conjugate compositions
JPWO2021112174A1 (en) * 2019-12-03 2021-06-10
US20230028062A1 (en) * 2019-12-06 2023-01-26 Rakuten Medical, Inc. Methods for enhancing immunity and tumor treatment
CN114981298A (en) 2019-12-12 2022-08-30 听治疗有限责任公司 Compositions and methods for preventing and treating hearing loss
CN111057063B (en) * 2019-12-19 2022-06-14 福州大学 Phthalocyanine derivative for targeted photodynamic therapy of acute lymphocytic leukemia and preparation method thereof
JPWO2021201284A1 (en) * 2020-04-02 2021-10-07
JP2023526033A (en) 2020-05-14 2023-06-20 ラクテン・メディカル，インコーポレイテッド Methods and compositions for treating tumors
CN113150774B (en) * 2021-04-30 2022-05-31 滨州学院 Near-infrared fluorescent molecular probe, preparation method thereof and application thereof in cell imaging
CN114409663B (en) * 2022-01-28 2023-05-30 福州大学 Zinc phthalocyanine 3-chloro-6 methylbenzo [ b ] thiophene-2-carboxylic acid conjugates targeting Mcl-1 enzyme and methods of making the same

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE547020A (en) 1955-04-20
US5494793A (en) 1986-12-15 1996-02-27 British Technology Group Usa Inc. Monomeric phthalocyanine reagents
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5196005A (en) 1991-11-26 1993-03-23 Pdt Systems, Inc. Continuous gradient cylindrical diffusion tip for optical fibers and method for making
JP2805723B2 (en) * 1994-06-09 1998-09-30 アイセロ化学株式会社 Shade container for high purity chemicals
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
US7521531B2 (en) 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
DE19717904A1 (en) 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
WO2001051924A2 (en) 2000-01-12 2001-07-19 Ventana Medical Systems, Inc. Method for determining the response to cancer therapy
WO2001057495A2 (en) 2000-02-01 2001-08-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health & Human Services Methods for predicting the biological, chemical, and physical properties of molecules from their spectral properties
WO2002100326A2 (en) 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
US20030031627A1 (en) 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
JP2003284757A (en) 2002-01-24 2003-10-07 Seputo:Kk Red-ray therapeutic device equipped with heater
AUPS146502A0 (en) 2002-03-28 2002-05-09 Traynor, Neil Methods and apparatus relating to improved visual recognition and safety
JP4074136B2 (en) 2002-05-29 2008-04-09 浜松ホトニクス株式会社 Fluorescence lifetime distribution image measuring apparatus and measuring method thereof
US7005518B2 (en) 2002-10-25 2006-02-28 Li-Cor, Inc. Phthalocyanine dyes
US20040120949A1 (en) 2002-11-08 2004-06-24 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
DE602004023183D1 (en) 2003-03-07 2009-10-29 Univ Texas PHOTODYNAMIC THERAPY PROVIDED AGAINST ANTIBODIES
WO2004099375A2 (en) 2003-04-30 2004-11-18 The General Hospital Corporation Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use therof
US20080253960A1 (en) 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
US8211883B2 (en) 2004-04-01 2012-07-03 Case Western Reserve University Topical delivery of phthalocyanines
CN101023084A (en) 2004-09-03 2007-08-22 亨斯迈先进材料（瑞士）有限公司 Compositions containing phthalocyanine dyes
US20080095950A1 (en) 2004-09-03 2008-04-24 Huntsman International Llc Compositions Containing Phthalocyanine Dyes
GB0504278D0 (en) 2005-03-02 2005-04-06 Khanzada Javed Personal adornment
US20130039861A1 (en) * 2005-04-06 2013-02-14 Immunomedics, Inc. Dye Conjugated Peptides for Fluorescent Imaging
US8227621B2 (en) * 2005-06-30 2012-07-24 Li-Cor, Inc. Cyanine dyes and methods of use
JP5627181B2 (en) 2005-09-07 2014-11-19 アルケミア オンコロジー ピーティーワイ リミテッド Therapeutic compositions comprising hyaluronan and therapeutic antibodies and methods of treatment
US20080095699A1 (en) 2006-10-20 2008-04-24 Shiying Zheng Imaging contrast agents using nanoparticles
DE102005059338A1 (en) 2005-12-08 2007-06-14 Carl Zeiss Jena Gmbh Method and arrangement for the examination of samples
US7993927B2 (en) 2006-07-03 2011-08-09 Beth Israel Deaconess Medical Center, Inc. Histology methods
JP2010522982A (en) 2007-03-29 2010-07-08 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ Light emitting device including an elastomer layer
GB0711560D0 (en) 2007-06-14 2007-07-25 Innova Biosciences Ltd Improvements in or relating to production of conjugates
WO2009038776A1 (en) 2007-09-18 2009-03-26 Victor Manneh Therapeutic nanoconjugates
JP2011500601A (en) 2007-10-12 2011-01-06 トランスモレキュラー， インコーポレイテッド Systemic administration of chlorotoxin drugs for tumor diagnosis and treatment
EP2244741B1 (en) 2008-01-18 2015-03-25 VisEn Medical, Inc. Fluorescent imaging agents
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
GB0819594D0 (en) 2008-10-24 2008-12-03 Univ Coimbrra Process
US8771741B2 (en) 2009-01-23 2014-07-08 The Penn State Research Foundation In vivo photodynamic therapy of cancer via a near infrared agent encapsulated in calcium phosphate nanoparticles
US8246565B2 (en) 2009-02-25 2012-08-21 The Invention Science Fund I, Llc Device for passively removing a target component from blood or lymph of a vertebrate subject
US8317737B2 (en) 2009-02-25 2012-11-27 The Invention Science Fund I, Llc Device for actively removing a target component from blood or lymph of a vertebrate subject
GB0904825D0 (en) 2009-03-20 2009-05-06 Photobiotics Ltd Biological materials and uses thereof
CN107252489A (en) 2009-04-13 2017-10-17 法国健康和医学研究院 HPV particles and application thereof
JP2012524153A (en) 2009-04-17 2012-10-11 ライコア インコーポレイテッド Fluorescence imaging using substituted cyanine dyes
EP2470887B1 (en) 2009-08-28 2020-03-11 VisEn Medical, Inc. Systems for tomographic imaging in diffuse media using a hybrid inversion technique
CN102781307B (en) 2009-09-22 2016-01-20 文森医学公司 For the system and method for the virtual refractive index match of diffusive medium
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
WO2011123742A1 (en) 2010-04-01 2011-10-06 Baylor College Of Medicine Non-radioactive agents for neuroblastoma imaging
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2012076631A1 (en) 2010-12-07 2012-06-14 Spectracure Ab System and method for interstitial photodynamic light therapy in combination with photosensitizers
US20140076404A1 (en) 2010-12-15 2014-03-20 Mei-Chee Tan Ir-activated photoelectric systems
US9018367B2 (en) 2011-04-12 2015-04-28 Board Of Regents, The University Of Texas System Single stranded DNA aptamers binding NF-κB/RelA
CN107929733A (en) * 2011-07-11 2018-04-20 美国政府(由卫生和人类服务部的部长所代表) Photosensitive antibody fluorescence rolls into a ball conjugate
EP2771333A4 (en) 2011-09-23 2015-05-20 Li Cor Inc Application of reduced dyes in imaging
RU2642287C2 (en) 2011-12-01 2018-01-24 Юниверсити Оф Кейп Таун Hpv chimeric particle
CN102585003B (en) 2012-02-06 2017-10-31 中国科学院福建物质结构研究所 The preparation method and applications of tumor-targeted photosensitive immunoconjugate
CA2866933C (en) 2012-03-21 2020-08-18 Rheinisch-Westfalische Technische Hochschule Aachen Novel photoimmunoconjugates for use in photodynamic therapy
US20160250337A9 (en) 2012-04-17 2016-09-01 Bahman Anvari Biomedical imaging and therapy using red blood cells
US9371362B2 (en) 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
JP2016026471A (en) 2012-11-27 2016-02-18 パナソニックヘルスケア株式会社 Cell discrimination/separation method and cell discrimination/separation device
WO2014089247A2 (en) 2012-12-04 2014-06-12 Sloan-Kettering Institute For Cancer Research Modular polymer hydrogel nanoparticles and methods of their manufacture
CN105102484B (en) 2013-01-30 2020-03-10 艾维拉斯生物科学公司 Selective delivery molecules and methods of use
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
AR095398A1 (en) * 2013-03-13 2015-10-14 Genentech Inc FORMULATIONS WITH REDUCED OXIDATION
CN105209058A (en) 2013-03-13 2015-12-30 豪夫迈·罗氏有限公司 Formulations with reduced oxidation
JP2016516774A (en) 2013-04-08 2016-06-09 ユニバーシティー オブ ノースキャロライナ アット チャペル ヒルＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ Photoresponsive compound
WO2014176284A1 (en) 2013-04-22 2014-10-30 Avelas Biosciences, Inc. Selective drug delivery compositions and methods of use
PT3046583T (en) 2013-09-18 2019-05-30 Aura Biosciences Inc Virus-like particle conjugates for treatment of tumors
US10232058B2 (en) 2013-10-14 2019-03-19 The Johns Hopkins University Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy
JP6487430B2 (en) 2013-10-21 2019-03-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Heteroaryl compounds as BTK inhibitors and their use
EP3099325A4 (en) 2014-01-31 2017-10-04 The General Hospital Corporation Dba Massachusetts General Hospital Methods of treating and imaging tumor micrometastases using photoactivatable immunoconjugates
JP2017507931A (en) 2014-02-05 2017-03-23 シーダーズ−サイナイ メディカル センター Method for treating cancer and infectious diseases and therapeutic composition
US10011587B2 (en) 2014-05-15 2018-07-03 The Methodist Hospital System Multivalent ligands targeting VEGFR
US9209062B1 (en) 2014-05-28 2015-12-08 Spintrac Systems, Inc. Removable spin chamber with vacuum attachment
AU2015271830B2 (en) 2014-06-02 2020-03-05 Rakuten Medical, Inc. Phthalocyanine probes and uses thereof
SG11201610052TA (en) 2014-08-08 2017-02-27 Us Health Photo-controlled removal of targets in vitro and in vivo
CN108137701A (en) 2015-08-07 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) For treating cancer for the near infrared light immunotherapy (NIR-PIT) for inhibiting cell
EP3827846A1 (en) 2015-08-18 2021-06-02 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
CN114699525A (en) * 2015-08-18 2022-07-05 乐天医药生技股份有限公司 Method for producing phthalocyanine dye conjugate and stable conjugate
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US10527771B2 (en) 2016-10-25 2020-01-07 Rakuten Medical, Inc. Frontal light diffusing device for use in photoimmunotherapy
EP3585433A4 (en) 2017-02-23 2020-12-30 Rakuten Medical, Inc. Therapeutic compositions and related methods for photoimmunotherapy
BR112020000184B8 (en) 2017-07-07 2022-09-27 Rakuten Medical Inc LIGHT DIFFUSION DEVICES FOR USE IN PHOTOIMMUNOTHERAPY
EP3668518A1 (en) 2017-08-18 2020-06-24 Li-Cor, Inc. Sonodynamic therapy
AU2019276572A1 (en) 2018-06-01 2020-12-24 Rakuten Medical, Inc. Phthalocyanine dye conjugate compositions
CN115943306A (en) 2019-03-29 2023-04-07 乐天医药生技股份有限公司 Methods and related biomarkers for photoimmunotherapy
US20220313822A1 (en) 2019-07-30 2022-10-06 Rakuten Medical, Inc. Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody
CN114585391A (en) 2019-08-07 2022-06-03 乐天医药生技股份有限公司 Cetuximab-IR 700 conjugate compositions
WO2021046100A1 (en) 2019-09-03 2021-03-11 Rakuten Medical, Inc. Methods for treatment using phthalocyanine dye-targeting molecule conjugates

Also Published As

Publication number Publication date
JP2019218374A (en) 2019-12-26
AU2016308286B2 (en) 2022-04-07
WO2017031363A2 (en) 2017-02-23
JP2021193111A (en) 2021-12-23
CN112494659A (en) 2021-03-16
US20190015510A1 (en) 2019-01-17
ES2889904T3 (en) 2022-01-14
CN114699525A (en) 2022-07-05
CN114681623A (en) 2022-07-01
CN112494659B (en) 2023-08-08
JP7425026B2 (en) 2024-01-30
AU2016308286A1 (en) 2018-03-08
JP2018528267A (en) 2018-09-27
WO2017031363A3 (en) 2017-04-20
CA2994871A1 (en) 2017-02-23
JP7055742B2 (en) 2022-04-18
JP2023182791A (en) 2023-12-26
CN108136215A (en) 2018-06-08
US11141483B2 (en) 2021-10-12
EP3337568B1 (en) 2021-08-04
DK3337568T3 (en) 2021-09-27
US20210401986A1 (en) 2021-12-30
JP6689439B2 (en) 2020-04-28
CN108136215B (en) 2022-04-29
JP7055742B6 (en) 2022-06-07
EP3777978A1 (en) 2021-02-17
NZ739788A (en) 2023-07-28
EP3337568A2 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
SG10202011033QA (en) Phthalocyanine dye conjugates and their storage
IL257669B (en) Psma-targeted nir dyes and their uses
IL258248A (en) Affinity-oligonucleotide conjugates and uses thereof
IL265919A (en) Pyrrolobenzodiazepine conjugates
IL248221B (en) Antibody-drug conjugates with high drug loading
GB201416112D0 (en) Pyrrolobenzodiazepines and conjugates thereof
GB201607478D0 (en) Pyrrolobenzodiazepine Conjugates
ZA201805526B (en) Pyrrolobenzodiazepine conjugates
IL261470A (en) Ca ix-target nir dyes and their uses
PL3303778T3 (en) Improvements in energy storage
GB201716426D0 (en) Energy storage
IL258759A (en) Anti-cd3-folate conjugates and their uses
GB201602363D0 (en) Pyrrolobenzodiazepine conjugates
GB201602359D0 (en) Pyrrolobenzodiazepine Conjugates
PT3470471T (en) Methine dyes
EP3160746A4 (en) Dye microenvironment
GB201619490D0 (en) Pyrrolobenzodiazepine conjugates
GB201615038D0 (en) Improvements in searching technology
ZA201804329B (en) Dye
GB201611481D0 (en) Energy storage
GB201607488D0 (en) Pyrrolobenzodiazepine Conjugates
GB201607485D0 (en) Pyrrolobenzodiazepine Conjugates
GB201602360D0 (en) Pyrrolobenzodiazepine conjugates
GB201514474D0 (en) Improvements in damper assemblies